All Oral Regimen of Oral Azacitidine and Venetoclax for Newly Diagnosed and Relapsed/Refractory AML

Panelists discuss how the all-oral regimen of oral azacitidine and venetoclax offers a promising treatment option for newly diagnosed and relapsed/refractory acute myeloid leukemia, highlighting its potential to improve patient outcomes and simplify treatment administration.

Now Viewing

EP: 1.All Oral Regimen of Oral Azacitidine and Venetoclax for Newly Diagnosed and Relapsed/Refractory AML

Recent Videos